BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 15749874)

  • 1. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.
    Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH
    J Immunol; 2005 Mar; 174(6):3408-15. PubMed ID: 15749874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
    Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
    Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.
    Lucas CL; Workman CJ; Beyaz S; LoCascio S; Zhao G; Vignali DA; Sykes M
    Blood; 2011 May; 117(20):5532-40. PubMed ID: 21422469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway.
    Haspot F; Fehr T; Gibbons C; Zhao G; Hogan T; Honjo T; Freeman GJ; Sykes M
    Blood; 2008 Sep; 112(5):2149-55. PubMed ID: 18577709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts.
    Hori J; Wang M; Miyashita M; Tanemoto K; Takahashi H; Takemori T; Okumura K; Yagita H; Azuma M
    J Immunol; 2006 Nov; 177(9):5928-35. PubMed ID: 17056517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed death-1 targeting can promote allograft survival.
    Ozkaynak E; Wang L; Goodearl A; McDonald K; Qin S; O'Keefe T; Duong T; Smith T; Gutierrez-Ramos JC; Rottman JB; Coyle AJ; Hancock WW
    J Immunol; 2002 Dec; 169(11):6546-53. PubMed ID: 12444166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism.
    Lee I; Wang L; Wells AD; Ye Q; Han R; Dorf ME; Kuziel WA; Rollins BJ; Chen L; Hancock WW
    J Immunol; 2003 Dec; 171(12):6929-35. PubMed ID: 14662900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
    Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
    J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.
    Fife BT; Pauken KE; Eagar TN; Obu T; Wu J; Tang Q; Azuma M; Krummel MF; Bluestone JA
    Nat Immunol; 2009 Nov; 10(11):1185-92. PubMed ID: 19783989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
    Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
    J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1/PD-1 signal deficiency promotes allogeneic immune responses and accelerates heart allograft rejection.
    Wang W; Carper K; Malone F; Latchman Y; Perkins J; Fu Y; Reyes J; Li W
    Transplantation; 2008 Sep; 86(6):836-44. PubMed ID: 18813109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes.
    Keir ME; Latchman YE; Freeman GJ; Sharpe AH
    J Immunol; 2005 Dec; 175(11):7372-9. PubMed ID: 16301644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo.
    Habicht A; Kewalaramani R; Vu MD; Demirci G; Blazar BR; Sayegh MH; Li XC
    Am J Transplant; 2007 Dec; 7(12):2683-92. PubMed ID: 17924994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation.
    Kanai T; Totsuka T; Uraushihara K; Makita S; Nakamura T; Koganei K; Fukushima T; Akiba H; Yagita H; Okumura K; Machida U; Iwai H; Azuma M; Chen L; Watanabe M
    J Immunol; 2003 Oct; 171(8):4156-63. PubMed ID: 14530338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD28-independent costimulation of T cells in alloimmune responses.
    Yamada A; Kishimoto K; Dong VM; Sho M; Salama AD; Anosova NG; Benichou G; Mandelbrot DA; Sharpe AH; Turka LA; Auchincloss H; Sayegh MH
    J Immunol; 2001 Jul; 167(1):140-6. PubMed ID: 11418642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.
    Carter L; Fouser LA; Jussif J; Fitz L; Deng B; Wood CR; Collins M; Honjo T; Freeman GJ; Carreno BM
    Eur J Immunol; 2002 Mar; 32(3):634-43. PubMed ID: 11857337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
    Blank C; Gajewski TF; Mackensen A
    Cancer Immunol Immunother; 2005 Apr; 54(4):307-14. PubMed ID: 15599732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo.
    Yang J; Riella LV; Chock S; Liu T; Zhao X; Yuan X; Paterson AM; Watanabe T; Vanguri V; Yagita H; Azuma M; Blazar BR; Freeman GJ; Rodig SJ; Sharpe AH; Chandraker A; Sayegh MH
    J Immunol; 2011 Aug; 187(3):1113-9. PubMed ID: 21697455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade.
    Reynoso ED; Elpek KG; Francisco L; Bronson R; Bellemare-Pelletier A; Sharpe AH; Freeman GJ; Turley SJ
    J Immunol; 2009 Feb; 182(4):2102-12. PubMed ID: 19201863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.